# EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide

> **NCT00132522** · PHASE1 · COMPLETED · sponsor: **EMD Serono** · enrollment: 45 (actual)

## Conditions studied

- Ovarian Cancer
- Colorectal Cancer
- Carcinoma, Non-small-cell Lung
- Prostate Cancer

## Interventions

- **DRUG:** EMD 273066

## Key facts

- **NCT ID:** NCT00132522
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-06
- **Final completion:** 2009-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2013-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00132522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00132522, "EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00132522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*